PURPOSE: To evaluate the prognostic significance of preoperative CA-125 levels on overall survival of patients with International Federation of Gynecology and Obstetrics (FIGO) stage I epithelial ovarian cancer (EOC). PATIENTS AND METHODS: Data from 518 patients with FIGO stage I EOC treated in seven gynecologic oncology centers throughout Australia between 1990 and 2002 were analyzed. Patients with borderline tumors and nonepithelial ovarian carcinomas were excluded, as were women in whom CA-125 had not been determined preoperatively. Preoperative CA-125 levels were studied in surgically staged and incompletely staged patients and compared with prognostic factors, such as substage, grade, and histologic type. Multivariate Cox models were calculated. RESULTS: CA-125 levels more than 30 U/mL were associated with higher grade, substage 1B and 1C, nonmucinous histologic type, and older age. In univariate analysis, higher histologic grade, the absence of surgical staging, and preoperative CA-125 levels more than 30 U/mL were associated with impaired survival. Multivariate analysis identified histologic grade, preoperative CA-125, and surgical staging as independent predictors for survival. In the subgroup of completely surgically staged patients, the 5-year overall survival rate was 82% (95% CI, 76% to 88%) for patients with CA-125 levels more than 30 U/mL and 95% (95% CI, 90% to 99%) for patients with CA-125 levels of 30 U/mL or less (P = .028). In the group of incompletely staged patients, the 5-year survival rates were similar for patients with elevated and normal serum CA-125 levels. CONCLUSION: Complete surgical staging, histologic grade, and preoperative serum CA-125 levels are independent prognostic factors and should be included in the decision making for chemotherapy.
PURPOSE: To evaluate the prognostic significance of preoperative CA-125 levels on overall survival of patients with International Federation of Gynecology and Obstetrics (FIGO) stage I epithelial ovarian cancer (EOC). PATIENTS AND METHODS: Data from 518 patients with FIGO stage I EOC treated in seven gynecologic oncology centers throughout Australia between 1990 and 2002 were analyzed. Patients with borderline tumors and nonepithelial ovarian carcinomas were excluded, as were women in whom CA-125 had not been determined preoperatively. Preoperative CA-125 levels were studied in surgically staged and incompletely staged patients and compared with prognostic factors, such as substage, grade, and histologic type. Multivariate Cox models were calculated. RESULTS: CA-125 levels more than 30 U/mL were associated with higher grade, substage 1B and 1C, nonmucinous histologic type, and older age. In univariate analysis, higher histologic grade, the absence of surgical staging, and preoperative CA-125 levels more than 30 U/mL were associated with impaired survival. Multivariate analysis identified histologic grade, preoperative CA-125, and surgical staging as independent predictors for survival. In the subgroup of completely surgically staged patients, the 5-year overall survival rate was 82% (95% CI, 76% to 88%) for patients with CA-125 levels more than 30 U/mL and 95% (95% CI, 90% to 99%) for patients with CA-125 levels of 30 U/mL or less (P = .028). In the group of incompletely staged patients, the 5-year survival rates were similar for patients with elevated and normal serum CA-125 levels. CONCLUSION: Complete surgical staging, histologic grade, and preoperative serum CA-125 levels are independent prognostic factors and should be included in the decision making for chemotherapy.
Authors: Dina Mury; Linn Woelber; Sabine Jung; Christine Eulenburg; Matthias Choschzick; Isabell Witzel; Joerg Schwarz; Fritz Jaenicke; Sven Mahner Journal: J Cancer Res Clin Oncol Date: 2011-02-23 Impact factor: 4.553
Authors: Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-01 Impact factor: 4.254
Authors: Alexander Melamed; Nancy L Keating; Joel T Clemmer; Amy J Bregar; Jason D Wright; David M Boruta; John O Schorge; Marcela G Del Carmen; J Alejandro Rauh-Hain Journal: Am J Obstet Gynecol Date: 2016-08-25 Impact factor: 8.661
Authors: Xiaoxiang Chen; Jing Zhang; Wenjun Cheng; Doo Young Chang; Jianfei Huang; Xuan Wang; Lizhou Jia; Daniel G Rosen; Wei Zhang; Da Yang; David M Gershenson; Anil K Sood; Robert C Bast; Jinsong Liu Journal: Int J Gynecol Cancer Date: 2013-06 Impact factor: 3.437